| Literature DB >> 29481809 |
Kevin Bourcier1, Antoine Italiano2.
Abstract
Metastatic soft-tissue sarcoma (STS), a devastating disease, has a median overall survival of only 12-18 months. Until recently, therapeutic options were limited and relied primarily on the use of anthracycline-based chemotherapy. Over the past two decades, improvement in the knowledge of the biology of STS has allowed the investigation of new therapeutic strategies including new cytotoxic agents, epigenetic drugs, specific targeted therapies, and immunotherapeutic treatments.Entities:
Keywords: Chemotherapy; Epigenetics; Immunotherapy; Metastatic disease; Sarcoma; Targeted therapy
Mesh：
Substances：
Year: 2018 PMID： 29481809 DOI： 10.1016/j.pharmthera.2018.02.014
Source DB: PubMed Journal: Pharmacol Ther ISSN： 0163-7258 Impact factor: 12.310